Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of New Zealand doctors in an oncology setting.
Oldfield et al.·Postgraduate medical journalImpact 2.4
UnklarGRADESehr niedrig12 Zitate
Stichproben = 45 Pat.
DauerNovember 2019 bis Januar 2020
EndpunktArzt-Patienten-Interaktionen
Verblindungn.a.
DesignKohortenstudie
”Kernaussage
Studie dokumentiert Häufigkeit von Patientenanfragen zu Cannabis-basierten Produkten (84% der Ärzte berichteten dies) und Wissenslücken bei Onkologen; es handelt sich um eine deskriptive Beobachtungsstudie ohne Interventionseffekt-Messung.
Zusammenfassung
Querschnitts-Survey unter n=45 Ärzten (Response Rate 85%) in 4 neuseeländischen Onkologie-Abteilungen, November 2019–Januar 2020. 37/44 (84%, 95% CI: 70–93%) berichteten Patienten-Anfragen zu Cannabis-Produkten; 43/44 (98%, 95% CI: 88–100%) berichteten Patienten-Nutzung von illegalem Cannabis für medizinische Symptome. Anfrage-Gründe: Schmerz, Übelkeit/Erbrechen, Krebsbehandlung. 36/44 (82%, 95% CI: 67–92%) äußerten künftige Verschreibungs-Bedenken, alle waren bereit, Produkte mit traditioneller medizinischer Provenienz zu nutzen.
P
PopulationÄrzte (Onkologie) in Neuseeland, n=45, aus vier Sekundärversorgungskrankenhäusern
I
InterventionQuerschnittserhebung zu Erfahrungen, Patienteninteraktionen und Wissensstand bezüglich medizinischem Cannabis
O
Outcome84% der Ärzte berichteten Patientenanfragen zur Verschreibung cannabisbasierter Produkte; 98% berichteten Patienten mit illegalem Cannabiskonsum zu medizinischen Zwecken; 73% kannten mind. ein cannabisbasiertes Produkt; 60% nannten mind. eine Indikation mit Wirksamkeitsevidenz; 82% äußerten Bedenken bezüglich zukünftiger Verschreibungen
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Sehr niedrig
Niedrigste GRADE-Stufe, die Effektschätzung bleibt unsicher.
Herabgestuft wegen
Ungenauigkeit
Qualitätsprofil
Größe★★★★★
Verblindung—
Effektstärke—
Zitate / Jahr★★★★★
Autoren
Oldfield K, Eathorne A, Tewhaiti-Smith J, Beasley R, Semprini A, Braithwaite I
Purpose Of Study: To explore the experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in New Zealand doctors in an oncology setting.
Study Design: An observational cross-sectional survey undertaken between November 2019 and January 2020 across four secondary-care hospital oncology departments within New Zealand (Auckland, Wellington, Christchurch and Dunedin). Participants were a convenience sample of doctors; consultants, registrars, medical officers of special status and house surgeons working in oncology departments. Of 53 individuals approached, 45 participated (85% Response Rate). The primary outcome was reporteddoctor-patient interactions. Secondary outcomes included knowledge of cannabis-based products, their efficacy, prescribing regulations and educational access.
Results: Of 44 doctors, 37 (84%, 95% CI: 70 to 93) reported patient requests to prescribe cannabis-based products and 43 (98%, 95% CI: 88 to 100) reported patients using illicit cannabis for medical symptoms. Primary request reasons were pain, nausea/vomiting and cancer treatment. 33/45 (73%, 95% CI: 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60%, 95% CI: 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82%, 95% CI: 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance.
Conclusion: In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical provenance; however, NZ-specific clinical and regulatory guidelines are essential to support patient discussions and appropriate prescribing.